1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Luye Pharma Group Ltd.

Luye Pharma Group Ltd.

LYPHF
Luye Pharma Group Ltd.US flagOther OTC
0.20
USD
- -
- -
815.28MMarket Cap

Total Valuation

Luye Pharma Group Ltd. carries a market capitalization of 815.28M, placing it among publicly traded companies globally. Its enterprise value stands at 324.43M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap815.28M
Enterprise Value324.43M

Share Statistics

Luye Pharma Group Ltd. currently has 492.76M shares outstanding.

Shares Outstanding492.76M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Enterprise Valuation

On an enterprise value basis, Luye Pharma Group Ltd. trades at an EV/EBITDA multiple of 1.34 and an EV/FCF ratio of 0.51. The EV/Sales ratio of 0.16 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 1.34 provides insight into valuation relative to core operating earnings.

EV / Sales0.16
EV / EBITDA1.34
EV / EBIT1.34
EV / FCF0.51

Financial Position

Luye Pharma Group Ltd. maintains a current ratio of 1.11, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 39.44, indicating elevated leverage, while an interest coverage ratio of 7.64 demonstrates adequate ability to service its debt obligations.

Current Ratio1.11
Quick Ratio0.41
Debt / Equity39.44
Debt / EBITDA2.43
Interest Coverage7.64

Financial Efficiency

Luye Pharma Group Ltd. posts a return on equity of 223.36 and a return on invested capital of 11.38.

Return on Equity (ROE)223.36
Return on Assets (ROA)7.69
Return on Invested Capital (ROIC)11.38
Return on Capital Employed (ROCE)27.43
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover3.60

Taxes

Over the trailing twelve months, Luye Pharma Group Ltd. has paid 24.77M in income taxes, reflecting an effective tax rate of 11.43.

Income Tax24.77M
Effective Tax Rate11.43

Stock Price Statistics

Luye Pharma Group Ltd.'s stock has declined approximately -23.84328% over the past 52 weeks. The 50-day moving average sits at 0.29, while the 200-day moving average is 0.34.

Beta (5Y)N/A
52-Week Price Change-23.84328%
50-Day Moving Average0.29
200-Day Moving Average0.34
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Luye Pharma Group Ltd. generated 2.01B in revenue and converted that into 181.32M in net income, yielding earnings per share of 0.39. EBITDA reached 242.73M, while operating income came in at 242.73M.

Revenue2.01B
Gross Profit1.66B
Operating Income242.73M
Pretax Income216.76M
Net Income181.32M
EBITDA242.73M
EBIT242.73M
Earnings Per Share (EPS)0.39

Balance Sheet

Luye Pharma Group Ltd. holds 398.28M in cash and equivalents against 589.60M in total debt, resulting in a net debt position of 201.92M. Total book value stands at 81.18M, with working capital of 109.95M providing operational flexibility.

Cash & Cash Equivalents398.28M
Total Debt589.60M
Net Debt201.92M
Equity (Book Value)81.18M
Book Value Per Share0.16
Working Capital109.95M

Cash Flow

Luye Pharma Group Ltd. produced 282.25M in operating cash flow over the past twelve months. After subtracting -325.41M in capital expenditures, free cash flow totaled -43.16M - equivalent to -0.09 per share.

Operating Cash Flow282.25M
Capital Expenditures-325.41M
Free Cash Flow-43.16M
FCF Per Share-0.09

Margins

Luye Pharma Group Ltd. operates with a gross margin of 82.79, reflecting its pricing power and cost economics. The operating margin of 12.08 and net profit margin of 9.02 provide insight into operational efficiency.

Gross Margin82.79
Operating Margin12.08
Pretax Margin10.78
Profit Margin9.02
EBITDA Margin12.08

Scores

Luye Pharma Group Ltd. posts an Altman Z-Score of 1.52, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.52